Driving T-cell Immunotherapy to Solid Tumors

Overview

Journal Nat Biotechnol

Specialty Biotechnology

Date 2018 Mar 7

PMID 29509745

Citations 66

Authors

Ken Garber

Affiliations

Soon will be listed here.

Citing Articles

The current landscape of optogenetics for the enhancement of adoptive T-cell therapy.

Smith G, Lee M, Jennings E, James J Discov Immunol. 2025; 4(1):kyae019.

PMID: 39959909 PMC: 11829120. DOI: 10.1093/discim/kyae019.

Adoptive T Cell Therapy Targeting MAGE-A4.

Chandora K, Chandora A, Saeed A, Cavalcante L Cancers (Basel). 2025; 17(3).

PMID: 39941782 PMC: 11815873. DOI: 10.3390/cancers17030413.

Targeting Cancer: Microenvironment and Immunotherapy Innovations.

Padzinska-Pruszynska I, Taciak B, Kiraga L, Smolarska A, Gorczak M, Kucharzewska P Int J Mol Sci. 2025; 25(24.

PMID: 39769334 PMC: 11679359. DOI: 10.3390/ijms252413569.

Remolding the tumor microenvironment by bacteria augments adoptive T cell therapy in advanced-stage solid tumors.

Zhu C, Liu C, Wu Q, Sheng T, Zhou R, Ren E Signal Transduct Target Ther. 2024; 9(1):307.

PMID: 39572541 PMC: 11582571. DOI: 10.1038/s41392-024-02028-3.

Influencing factors and solution strategies of chimeric antigen receptor T-cell therapy (CAR-T) cell immunotherapy.

Wang Z, Zhou L, Wu X Oncol Res. 2024; 32(9):1479-1516.

PMID: 39220130 PMC: 11361912. DOI: 10.32604/or.2024.048564.

References

Morgan R, Chinnasamy N, Abate-Daga D, Gros A, Robbins P, Zheng Z . Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013; 36(2):133-51. PMC: 3581823. DOI: 10.1097/CJI.0b013e3182829903. View

Lu Y, Yao X, Crystal J, Li Y, El-Gamil M, Gross C . Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res. 2014; 20(13):3401-10. PMC: 4083471. DOI: 10.1158/1078-0432.CCR-14-0433. View

Hedrick S, Cohen D, Nielsen E, Davis M . Isolation of cDNA clones encoding T cell-specific membrane-associated proteins. Nature. 1984; 308(5955):149-53. DOI: 10.1038/308149a0. View

Morgan R, Dudley M, Wunderlich J, Hughes M, Yang J, Sherry R . Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006; 314(5796):126-9. PMC: 2267026. DOI: 10.1126/science.1129003. View

Parkhurst M, Yang J, Langan R, Dudley M, Nathan D, Feldman S . T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol Ther. 2010; 19(3):620-6. PMC: 3048186. DOI: 10.1038/mt.2010.272. View

Yanagi Y, Yoshikai Y, Leggett K, Clark S, Aleksander I, Mak T . A human T cell-specific cDNA clone encodes a protein having extensive homology to immunoglobulin chains. Nature. 1984; 308(5955):145-9. DOI: 10.1038/308145a0. View

Tran E, Turcotte S, Gros A, Robbins P, Lu Y, Dudley M . Cancer immunotherapy based on mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014; 344(6184):641-5. PMC: 6686185. DOI: 10.1126/science.1251102. View

Dembic Z, Haas W, Weiss S, McCubrey J, Kiefer H, von Boehmer H . Transfer of specificity by murine alpha and beta T-cell receptor genes. Nature. 1986; 320(6059):232-8. DOI: 10.1038/320232a0. View

Deniger D, Pasetto A, Tran E, Parkhurst M, Cohen C, Robbins P . Stable, Nonviral Expression of Mutated Tumor Neoantigen-specific T-cell Receptors Using the Sleeping Beauty Transposon/Transposase System. Mol Ther. 2016; 24(6):1078-1089. PMC: 4923320. DOI: 10.1038/mt.2016.51. View

10.

Linette G, Stadtmauer E, Maus M, Rapoport A, Levine B, Emery L . Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 2013; 122(6):863-71. PMC: 3743463. DOI: 10.1182/blood-2013-03-490565. View

11.

Schmitt T, Aggen D, Stromnes I, Dossett M, Richman S, Kranz D . Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection. Blood. 2013; 122(3):348-56. PMC: 3716200. DOI: 10.1182/blood-2013-01-478164. View

12.

Robbins P, Morgan R, Feldman S, Yang J, Sherry R, Dudley M . Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011; 29(7):917-24. PMC: 3068063. DOI: 10.1200/JCO.2010.32.2537. View

13.

Fesnak A, June C, Levine B . Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer. 2016; 16(9):566-81. PMC: 5543811. DOI: 10.1038/nrc.2016.97. View

14.

Roybal K, Rupp L, Morsut L, Walker W, McNally K, Park J . Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits. Cell. 2016; 164(4):770-9. PMC: 4752902. DOI: 10.1016/j.cell.2016.01.011. View

15.

Corrales L, McWhirter S, Dubensky Jr T, Gajewski T . The host STING pathway at the interface of cancer and immunity. J Clin Invest. 2016; 126(7):2404-11. PMC: 4922692. DOI: 10.1172/JCI86892. View

16.

Oda S, Daman A, Garcia N, Wagener F, Schmitt T, Tan X . A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia. Blood. 2017; 130(22):2410-2419. PMC: 5709784. DOI: 10.1182/blood-2017-04-777052. View

17.

Holler P, Holman P, Shusta E, OHerrin S, Wittrup K, Kranz D . In vitro evolution of a T cell receptor with high affinity for peptide/MHC. Proc Natl Acad Sci U S A. 2000; 97(10):5387-92. PMC: 25838. DOI: 10.1073/pnas.080078297. View